Tag: oncology
Sanofi will collaborate in oncology with the Chinese group, Innovent Biologics – 08/04/2022 at 17:52
(AOF) – Sanofi and Innovent Biologics have announced the establishment of a collaboration to bring innovative medicines to patients with difficult-to-treat cancers in China. The two companies are committed to…
Sanofi forges a strategic partnership in oncology with the Chinese Innovent Biologics
PARIS (Agefi-Dow Jones)–Sanofi and biopharmaceutical company Innovent Biologics have entered into a strategic collaboration agreement to intensify the development and commercialization of new medicines for cancer patients in China. This…
“Inequality in cancer in France is the variation in oncology of the famous medical deserts”
Lhe World Health Organization (WHO) is formal: “How the phenomenon of inequalities in cancer evolves and changes over time (…) concerns everyone, but the most disadvantaged people are particularly affected.…
French oncologist Etienne Brain, specialist in seniors, awarded by the American Association of Clinical Oncology
Etienne Brain, medical oncologist at the Institut Curie on the Saint-Cloud site (Hauts-de-Seine), at the René-Huguenin hospital, in 2017. URIEL CHANTRAINE/INSTITUT CURIE In 2005, Doctor Etienne Brain received a 79-year-old…
Celyad Oncology will give a presentation at the HC Wainwright Global Investment Conference – 05/17/2022 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the research and development of CAR T (Chimeric Antigen Receptor) cell therapies…
AstraZeneca: extended oncology partnership with Proteros
(CercleFinance.com) – The German scientific company Proteros announced on Monday that it would deepen its collaboration in the field of oncology with the biopharmaceutical giant AstraZeneca. This new step, which…
AstraZeneca: Extended Oncology Partnership with Proteros
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Celyad Oncology Reports First Quarter 2022 Financial Results and Recent Company Progress – 05/05/2022 at 22:01
• Recruitment continues in the complementary cohorts of the IMMUNICY-1 dose-escalation Phase 1 trial for the allogeneic shRNA-based CAR T candidate, CYAD-211, for patients with relapsed/refractory Multiple Myeloma (MM r…
Bayer: New Head of Oncology Development
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Celyad Oncology presents its Financial Results for the year 2021 as well as recent business highlights – 03/24/2022 at 21:08
• Phase 1 of the IMMUNICY-1 trial demonstrated encouraging data for CYAD-211, including a good safety profile and signs of clinical activity in patients with relapsed/refractory Multiple Myeloma (MM r/r…
Celyad Oncology announces voluntary suspension of Phase 1b trial CYAD-101-002 – 02/28/2022 at 08:30
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the research and development of T cell-based CAR T cell therapies (…
Celyad Oncology announces its participation in a conference in February 2022 – 01/31/2022 at 22:05
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of CAR T cell therapies based on T lymphocytes (Chimeric…